Dat	re:2022/8/1		
	ur Name: Junni		
Ma pro	nuscript Title: The non-	coding RNA (ncRNA)-med related with tumor immu	iated high expression of polycomb group factor 1 (PCGF1) is nity infiltration in liver hepatocellular carcinoma
rela par to t	ated to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	e following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to t	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	

Time frame: past 36 months

X\_None

X\_None

X\_\_None

processing charges, etc.)

No time limit for this item.

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

2

3

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending meetings and/or travel	XNone	
	G ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Dia -		uflick of intercet in the fel	laudea hau
Piea	se summarize the above co	milict of interest in the fo	iowing box:

١	lone.			

Dat	e:2022/8/1						
You	r Name:Yingx	xun Xu					
			liated high expression of polycomb group factor 1 (PCGF1) is a unity infiltration in liver hepatocellular carcinoma				
Ma	nuscript number (if known):						
rela par to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.				
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current				
to t	he author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains of the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive nedication, even if that medication is not mentioned in the manuscript.						
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other items,				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initi	ial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone					
	medical writing, article processing charges, etc.)  No time limit for this item.						
		Time ( )	at 25 manths				
2	Grants or contracts from any entity (if not indicated	Time frame: pas	st 36 months				
2		_	st 36 months				

Consulting fees

X\_\_None

4

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
6	educational events Payment for expert	X None	
	testimony		
	·		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or	X_None	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None.			

Date	e:2022/8/1		
	r Name: Cheng		
prog		related with tumor immu	iated high expression of polycomb group factor 1 (PCGF1) is a nity infiltration in liver hepatocellular carcinoma
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	at 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	

Consulting fees

X\_\_None

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
6	educational events Payment for expert	X None	
	testimony		
	·		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or	X_None	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the foll	owing box:

None.			

Dat	e:2022/8/	1	
	r Name:Shiw		
Mai pro	nuscript Title: The non	-coding RNA (ncRNA)-media rrelated with tumor immun	ited high expression of polycomb group factor 1 (PCGF1) is ity infiltration in liver hepatocellular carcinoma
rela part to t	ted to the content of your ties whose interests may be ransparency and does not i	manuscript. "Related" mear e affected by the content of	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	following questions apply nuscript only.	to the author's relationship	s/activities/interests as they relate to the <u>current</u>
to t	he epidemiology of hyperte		efined broadly. For example, if your manuscript pertains II relationships with manufacturers of antihypertensive e manuscript.
	em #1 below, report all su time frame for disclosure i	-	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	
-	manuscript (e.g., funding,		

Time frame: past 36 months

X\_None

X\_None

X\_\_None

provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** 

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

2

3

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
	meetings unapprocedure.		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	V None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	se summarize the above co	nflict of interest in the fol	lowing box:

None.		

Date	e:2022/8/1		
You	r Name: Jian X	Kie	
Mar pro	nuscript Title: The non-	coding RNA (ncRNA)-med related with tumor immu	iated high expression of polycomb group factor 1 (PCGF1) is a nity infiltration in liver hepatocellular carcinoma
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	at 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X\_\_None

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
_	educational events			
6	Payment for expert testimony	XNone		
-		V N		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	XNone		
13	services Other financial or non-	X None		
13	financial interests			
	illiancial illici coto			
Plea	Please summarize the above conflict of interest in the following box:			

None.

Date	e:2022/8/1					
You	r Name: Hrish	ikesh Samant				
prog	Manuscript Title: The non-coding RNA (ncRNA)-mediated high expression of polycomb group factor 1 (PCGF1) is a prognostic biomarker and is correlated with tumor immunity infiltration in liver hepatocellular carcinoma Manuscript number (if known):					
relat part to tr	ted to the content of your r ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.			
	following questions apply t uscript only.	to the author's relationshi	ps/activities/interests as they relate to the current			
to th	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.			
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initi	al planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone				
		Time frame: pas	st 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	XNone				

Consulting fees

\_X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
4.2	services Other financial or non-	V. Nana	
13	financial interests	XNone	
	illiancial interests		
Dias	ase summarize the above co	afflict of interest in the fa	llowing hove
Piec	ise suilillalize the above co	milici of interest in the 10	nowing box.
	lana.		
	lone.		

\_2022/8/1\_

Date:\_\_

You	r Name: Xuezl	ni xin	
			ated high expression of polycomb group factor 1 (PCGF1) is a
		_	nity infiltration in liver hepatocellular carcinoma
•	nuscript number (if known):		·
rela part to t rela	ited to the content of your naties whose interests may be ransparency and does not notionship/activity/interest, it	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I is preferable that you do s	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of the manuscript about whether to list a so.  s/activities/interests as they relate to the current
<u>mar</u>	nuscript only.		
to to med	he epidemiology of hyperted dication, even if that medica	nsion, you should declare a ition is not mentioned in th port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.  In this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initial	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V No.	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X None		
ם	lectures, presentations,	xNone		
	l			
	speakers bureaus,			
	manuscript writing or			
_	educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment, materials, drugs, medical	X None		
	writing, gifts or other			
	services			
13	Other financial or non- financial interests	X None		
Dlac	Please summarize the above conflict of interest in the following box:			
ricase summarize the above connect of interest in the following box.				
	News			
	lone.			